Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2022-03-28 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Jyseleca® approved in Japan for ulcerative colitis
Regulatory Filings Classification · 95% confidence The document is a press release dated March 28, 2022, announcing that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved a second indication for the drug Jyseleca (filgotinib) for ulcerative colitis. The text details the approval, the supporting clinical study (SELECTION), and outlines the commercialization agreements between Galapagos, Gilead, Eisai, and EA Pharma. This format—a formal announcement of a significant corporate/product development, often released via wire services (implied by the structure and contact info)—is characteristic of an Earnings Release (ER) if it were focused on financial results, or more generally, a Regulatory Filing (RNS) if it's a broad announcement not covered by other specific codes. Since this is a specific, time-sensitive announcement about a regulatory milestone (drug approval) and partnership updates, and it is not a full financial report (10-K, IR), a management discussion (MDA), or a transcript (CT), the most appropriate general category for significant, non-financial regulatory news that doesn't fit elsewhere is RNS (Regulatory Filings). It is not an ER because it focuses on regulatory approval, not financial performance highlights. It is not an RPA because it is the substance of the news, not just an announcement that a report is attached.
2022-03-28 Dutch
Jyseleca® approved in Japan for ulcerative colitis
Regulatory Filings Classification · 100% confidence The document is a press release dated March 28, 2022, announcing the approval of a drug (Jyseleca) in Japan for a new indication (ulcerative colitis). It details the basis for approval (Phase 2b/3 SELECTION study), commercialization plans, and includes standard sections like 'About filgotinib', 'About the filgotinib collaboration', and 'Forward-looking statements'. This format is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/product news. Since it is a specific announcement of results/approval rather than a comprehensive periodic report (like 10-K or IR), and it is not a transcript (CT) or a presentation (IP), the most fitting category is Earnings Release (ER), as these announcements often accompany or precede quarterly results, or serve as major operational updates. However, upon reviewing the definitions, this is a specific regulatory/product update, not explicitly an 'Earnings Release' which usually focuses on financial performance metrics (revenue, EPS). It is a significant operational announcement. Given the options, it is a general corporate announcement. If it were a short announcement linking to a full report, it would be RPA/RNS. Since it contains substantial detail about the approval and study data, it is more than just a link announcement. It is a detailed operational update. In the absence of a specific 'Product/Regulatory Update' category, 'Regulatory Filings' (RNS) is often used for non-standard, material announcements, or 'ER' if it's treated as a major operational highlight release. Given the content focuses on a regulatory approval and clinical data, RNS (Regulatory Filings) is a strong candidate as a catch-all for material, non-periodic announcements. However, many companies issue these types of announcements alongside or in place of a formal ER. Since it is a detailed press release announcing a major event (drug approval), and not a standard periodic financial report, I will classify it as a Regulatory Filing (RNS) as it is a material announcement that doesn't fit the specific financial report types (10-K, IR, ER).
2022-03-28 English
6-K Filing
Regulatory Filings
2022-03-28 English
Correction: Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings
Report Publication Announcement Classification · 99% confidence The document is titled "Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders' meetings". It explicitly mentions the publication of the 'annual report for the financial year 2021' and the announcement of the 'extraordinary and annual shareholders' meetings' scheduled for April 26, 2022. The content details proposals for the meetings, such as adopting a one-tier board structure and appointing new directors. Since the document is an announcement that covers both the release of the Annual Report (which would typically be a 10-K or similar comprehensive filing) AND the convening/agenda for the AGM, it serves multiple purposes. However, the primary focus is the announcement of the meetings and the related governance changes (board structure, director appointments), which are key components of AGM/Shareholder materials. The document also mentions the 2021 Form 20-F filing (the US equivalent of a 10-K) is available elsewhere. Given the strong emphasis on convening the shareholders' meetings and detailing the agenda items (board changes, voting), the most specific and relevant classification is AGM-R (AGM Information), as it is directly related to the meeting itself, even though it also announces the availability of the Annual Report.
2022-03-25 English
Correction: Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings
Report Publication Announcement Classification · 95% confidence The document is a press release announcing the publication of the 2021 Annual Report and the scheduling of the Annual General Meeting (AGM). It provides links to the actual reports rather than containing the full financial statements itself. It also details the agenda for the upcoming shareholder meetings, including board changes and governance structure updates. Per the 'Menu vs Meal' rule, this is an announcement of reports and meetings, not the report itself, making it a Report Publication Announcement (RPA). FY 2021
2022-03-25 English
6-K Filing
Regulatory Filings
2022-03-25 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.